Marker Therapeutics, Inc.
Pharmaceutical ManufacturingTexas, United States11-50 Employees
Marker Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors. Its approach centers on expanding non-engineered, tumor-specific T cells that recognize multiple tumor-associated antigens, with the goal of producing broad anti-tumor activity after infusion while aiming for lower manufacturing complexity and toxicity compared with engineered CAR-T or TCR therapies. The company positions its product portfolio as having a compelling therapeutic profile due to the absence of genetic modification in its T cells, which may translate into reduced cost and improved safety, alongside meaningful clinical benefit. Headquartered in Houston, Texas, Marker Therapeutics operates within the immuno-oncology field and targets both blood cancers and solid tumors. It engages in collaborations and activities typical of a clinical-stage biotech, including partnerships with contract manufacturing organizations and participation in industry conferences. The organization maintains a relatively small to mid-sized workforce and is led by a management team focused on advancing its MT-601 and related multi-antigen–recognizing T cell therapies through development and early clinical evaluation.
1-888-653-2347 
support@leadiq.com 
